A major weapon against cancer

  • The cancer immunotherapy market for checkpoint inhibitors will increase to nearly $9 billion across the world’s major pharmaceutical markets in 2022.
  • News of the successes of immunotherapies dominated the 2014 ASCO meeting.
  • Immune approaches to cancer therapy have been validated by the recent approval of drugs such as Yervoy® and Provenge®.
  • New immune modulators such as Anti PD-1 Keytruda®/PD-L1 mAb’s that boost T-cell activity in response to tumors are high priority development programs for Big Pharma.
  • Analysts estimate that cancer immunotherapies could account for $35 billion annually within 10 years

The Susavion advantage

  • Current therapies with monoclonal antibodies attack a single target and are very costly to produce. Side effects are significant but manageable.
  • Susavion’s multivalent technology engages strategic targets on multiple cell types, instead of one, and activates key immune cells.
  • Susavion’s platform drugs are produced synthetically, are relatively inexpensive, stable, and easily distributed world-wide.
  • Susavion’s drugs have broad application against cancers, low toxicity, and thus are potentially game changes.